NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

GUIDE-HF STUDY DATA SHOW ABBOTT’S CARDIOMEMS™ DEVICE CAN IMPROVE CARE FOR MORE PATIENTS WITH HEART FAILURE

by Ed Johnson
August 28, 2021
A A

– The GUIDE-HF study examined the potential impact of Abbott’s CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device

– Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and reduce hospitalizations, especially for patients suffering from earlier stages of the disease

Abbott (NYSE: ABT) today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS™ HF System in people living with NYHA Class II, III and IV heart failure. Data adjusted for the impact of COVID-19 show a strong reduction in a composite endpoint of heart failure hospitalizations, emergency visits and death in a broad range of patients, suggesting new benefits from the CardioMEMS device.

CardioMEMS is currently approved for use in NYHA Class III patients with a prior heart failure hospitalization within the last year. The GUIDE-HF study examined an expanded patient population, including patients with NYHA Class II and Class IV heart failure, to evaluate the device in patients in earlier or later-stage disease progression.

GUIDE-HF is one of many large trials conducted amid the COVID-19 pandemic, when healthcare systems experienced significant disruption. Heart failure patients are at a heightened risk of COVID-19 and – as a result – experienced changes to their care management and hospitalization during the pandemic. An analysis of the full one-year data set, of which 28% of the follow-up data was collected during COVID-19, showed CardioMEMS-guided patients had a lower composite endpoint rate of total heart failure events and death compared to the study’s control group, which was not statistically significant. In an analysis of data adjusted for the impact of COVID-19 (captured prior to March 13, 2020 – the date the U.S. national emergency was declared), CardioMEMS demonstrated a significant 19% reduction in the study’s composite endpoint and a 28% reduction in heart failure hospitalizations.

The results of GUIDE-HF were presented at the ESC Congress 2021 (organized by the European Society of Cardiology) and simultaneously published in The Lancet. Based on the strength of the GUIDE-HF data, Abbott has filed a Premarket Approval (PMA) supplement with the U.S. Food and Drug Administration (FDA) for consideration of an expanded indication for the CardioMEMS device.

The CardioMEMS HF System includes a small sensor the size of a paperclip that, once placed in the pulmonary artery during a minimally invasive procedure, monitors for pressure changes that indicate worsening heart failure even before patients feel symptoms. The CardioMEMS sensor connects to a system that remotely provides daily pressure readings to a patient’s clinical team, allowing physicians to make therapy changes to combat worsening heart failure.

“The two most important strategies in treating heart failure are helping doctors stay ahead of the condition as it progresses and keeping people stable and out of the hospital and emergency room. The GUIDE-HF trial shows that Abbott’s CardioMEMS device has a role in both,” said Philip B. Adamson, M.D., chief medical officer of Abbott’s heart failure business. “This tiny cardiac sensor, coupled with the increased improvements in informed telemedicine, can have a tremendous impact on helping people at all stages of heart failure live their healthiest lives.”

GUIDE-HF Data Overview
Though not designed to assess the benefits of CardioMEMS in specific patient sub-groups, when adjusted for the impact of COVID-19, the GUIDE-HF study suggests potential benefits of the device in new groups of patients, including: 

  • Patients in earlier stages of heart disease. GUIDE-HF data suggests better outcomes in Class II patients when their therapy is guided by pulmonary pressure monitoring, with a 34% reduction in heart failure hospitalizations, emergency visits and death.
  • Specific patient groups. GUIDE-HF also demonstrated a relative risk reduction for both women (33%) and African American patients (41%), two patient segments disproportionately impacted by effects of heart failure.
  • Patients at risk of potential hospitalization. GUIDE-HF showed a 25% reduction in hospitalization or emergency department visits in patients without a prior heart failure hospitalization but who undergo blood tests that show elevated levels of a biomarker known as B-type Natriuretic Peptide (BNP), which indicates worsening heart failure.

“Clinicians have seen firsthand the importance of CardioMEMS in helping them proactively manage heart failure to keep patients out of the hospital, and the GUIDE-HF trial showed the device provides benefits for more patients than ever before,” said JoAnn Lindenfeld, M.D., primary investigator for the GUIDE-HF trial and director of advanced heart failure at Vanderbilt University Medical Center in Nashville, Tenn. “Even with the disruptions that we saw as a result of the COVID-19 pandemic, this trial was still able to show significant reductions in heart failure hospitalizations and reduced emergency visits with pulmonary pressure sensor monitoring.”

Tags: < Corporate Events
ShareTweetShareSend

Related Industries

Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023
Healthcare

Medtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution

May 17, 2023
Healthcare

Amgen Responds to Ftc Action RE: Proposed Acquisition Of Horizon Therapeutics

May 17, 2023
Healthcare

Cardinal Health Canada to open new distribution center in Ontario

May 11, 2023
Healthcare

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

May 10, 2023
Healthcare

Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

May 10, 2023

Morgan Stanley Capital Partners Acquires RowCal

May 2, 2023

...

DuPont Publishes 2023 Sustainability Report

May 2, 2023

...

Johnson Controls and HD Supply announce national distribution collaboration for residential HVAC equipment

May 2, 2023

...

Dow and New Energy Blue to develop renewable plastic materials from corn residue.

Dow and New Energy Blue announce collaboration to develop renewable plastic materials from corn residue

May 26, 2023

...

Kimberly-Clark Professional Announces Greenovation Awards For Sustainability Leadership And Waste Reduction

May 6, 2023

...

Henkel opens Adhesive Technologies Technology Center in Bridgewater

May 17, 2023

...

Best Buy makes DiversityInc Top 50 Companies for Diversity list

May 5, 2023

...

Ford EV Customers To Gain Access to 12,000 Tesla Superchargers; Company to Add North American Charging Standard Port in Future EVs

May 26, 2023

...

US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults

May 4, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.